-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Benzinga·09/24/2026 13:59:03
Diffusion vocale
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.